Key points from article :
Gerostate Alpha is a Buck Institute start up.
Will screen molecules for ageing, in as unbiased a way as possible.
"Identifying interventions that attenuate multiple ageing indications simultaneously" - Simon Melov, Founder.
Thousands of compounds are screened through a high throughput screen.
"Derivatives are prepped into lead candidates to move into our preclinical mouse models".
“Our whole approach is to screen for phenotypes - not a specific pathway we’re focusing on".
“Our phenotype is lifespan - magnitude of the increase in lifespan"
Investors want well-characterised targets for new drugs but Gerostate Alpha is committed to its mission.
